The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 29, 2020
Filed:
Dec. 14, 2018
Applicant:
Applied Molecular Transport Inc., South San Francisco, CA (US);
Inventors:
Randall J. Mrsny, Los Altos Hills, CA (US);
Tahir Mahmood, Burlingame, CA (US);
Assignee:
Applied Molecular Transport Inc., South San Francisco, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/45 (2006.01); C07K 14/54 (2006.01); A61K 38/16 (2006.01); A61K 38/20 (2006.01); A61K 38/26 (2006.01); A61K 38/48 (2006.01); A61K 38/49 (2006.01); A61K 38/50 (2006.01); A61K 38/51 (2006.01); A61K 38/27 (2006.01); A61K 38/17 (2006.01); C07K 16/24 (2006.01);
U.S. Cl.
CPC ...
A61K 38/45 (2013.01); A61K 38/164 (2013.01); A61K 38/166 (2013.01); A61K 38/1793 (2013.01); A61K 38/20 (2013.01); A61K 38/2066 (2013.01); A61K 38/26 (2013.01); A61K 38/27 (2013.01); A61K 38/482 (2013.01); A61K 38/49 (2013.01); A61K 38/50 (2013.01); A61K 38/51 (2013.01); C07K 14/5428 (2013.01); C07K 16/241 (2013.01); C12Y 204/02036 (2013.01); C12Y 304/21068 (2013.01); C12Y 304/21073 (2013.01); C12Y 305/04004 (2013.01); C12Y 402/02001 (2013.01); C07K 2317/76 (2013.01); C07K 2319/00 (2013.01); C07K 2319/21 (2013.01); C07K 2319/30 (2013.01); C07K 2319/32 (2013.01); C07K 2319/50 (2013.01); C07K 2319/55 (2013.01); C07K 2319/60 (2013.01); C07K 2319/90 (2013.01);
Abstract
The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.